Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Andreas Scherer
Affiliation
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
ORCID
Career Start Year
1995
Papers
56
H Index
22
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
36229534
Glomerular proteomic profiling of kidney biopsies with hypertensive nephropathy reveals a signature of disease progression.
Hypertens Res
2023
36229534
Glomerular proteomic profiling of kidney biopsies with hypertensive nephropathy reveals a signature of disease progression.
Hypertens Res
2023
37884999
The Quartet Data Portal: integration of community-wide resources for multiomics quality control.
Genome Biol
2023
37884999
The Quartet Data Portal: integration of community-wide resources for multiomics quality control.
Genome Biol
2023
35118162
Consensus guidelines for the validation of qRT-PCR assays in clinical research by the CardioRNA consortium.
Mol Ther Methods Clin Dev
2022
36310597
Tackling the translational challenges of multi-omics research in the realm of European personalised medicine: A workshop report.
Front Mol Biosci
2022
35931808
A multiomics disease progression signature of low-risk ccRCC.
Sci Rep
2022
34980216
Assessing reproducibility of inherited variants detected with short-read whole genome sequencing.
Genome Biol
2022
35118162
Consensus guidelines for the validation of qRT-PCR assays in clinical research by the CardioRNA consortium.
Mol Ther Methods Clin Dev
2022
36310597
Tackling the translational challenges of multi-omics research in the realm of European personalised medicine: A workshop report.
Front Mol Biosci
2022
35931808
A multiomics disease progression signature of low-risk ccRCC.
Sci Rep
2022
34980216
Assessing reproducibility of inherited variants detected with short-read whole genome sequencing.
Genome Biol
2022
33091118
Biomarker Research and Development for Coronavirus Disease 2019 (COVID-19): European Medical Research Infrastructures Call for Global Coordination.
Clin Infect Dis
2021
32055842
Exploration of databases and methods supporting drug repurposing: a comprehensive survey.
Brief Bioinform
2021
33846644
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology.
Nat Biotechnol
2021
33863366
A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency.
Genome Biol
2021
33863344
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions.
Genome Biol
2021
33091118
Biomarker Research and Development for Coronavirus Disease 2019 (COVID-19): European Medical Research Infrastructures Call for Global Coordination.
Clin Infect Dis
2021
34789871
Reporting guidelines for human microbiome research: the STORMS checklist.
Nat Med
2021
34504347
Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing.
Nat Biotechnol
2021
34504346
Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing.
Nat Biotechnol
2021
34949218
Author Correction: The SEQC2 epigenomics quality control (EpiQC) study.
Genome Biol
2021
34930263
AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease.
Cancer Cell Int
2021
34872606
The SEQC2 epigenomics quality control (EpiQC) study.
Genome Biol
2021
33846644
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology.
Nat Biotechnol
2021
33863366
A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency.
Genome Biol
2021
33863344
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions.
Genome Biol
2021
34949218
Author Correction: The SEQC2 epigenomics quality control (EpiQC) study.
Genome Biol
2021
34872606
The SEQC2 epigenomics quality control (EpiQC) study.
Genome Biol
2021
34930263
AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease.
Cancer Cell Int
2021
34789871
Reporting guidelines for human microbiome research: the STORMS checklist.
Nat Med
2021
34504347
Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing.
Nat Biotechnol
2021
34504346
Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing.
Nat Biotechnol
2021
32055842
Exploration of databases and methods supporting drug repurposing: a comprehensive survey.
Brief Bioinform
2021
31134766
AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction.
Physiol Rep
2019
31134766
AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction.
Physiol Rep
2019
30838877
Transcriptome-proteome integration of archival human renal cell carcinoma biopsies enables identification of molecular mechanisms.
Am J Physiol Renal Physiol
2019
30838877
Transcriptome-proteome integration of archival human renal cell carcinoma biopsies enables identification of molecular mechanisms.
Am J Physiol Renal Physiol
2019
29534467
Expanding the Utilization of Formalin-Fixed, Paraffin-Embedded Archives: Feasibility of miR-Seq for Disease Exploration and Biomarker Development from Biopsies with Clear Cell Renal Cell Carcinoma.
Int J Mol Sci
2018
30039368
Detection of CNVs in NGS Data Using VS-CNV.
Methods Mol Biol
2018
29534467
Expanding the Utilization of Formalin-Fixed, Paraffin-Embedded Archives: Feasibility of miR-Seq for Disease Exploration and Biomarker Development from Biopsies with Clear Cell Renal Cell Carcinoma.
Int J Mol Sci
2018
30039368
Detection of CNVs in NGS Data Using VS-CNV.
Methods Mol Biol
2018
28596300
Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis.
Physiol Rep
2017
28596300
Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis.
Physiol Rep
2017
28450744
Bridging the translational innovation gap through good biomarker practice.
Nat Rev Drug Discov
2017
28490671
Matched preclinical designs for improved translatability.
Sci Transl Med
2017
29084770
Renal carcinoma/kidney progenitor cell chimera organoid as a novel tumorigenesis gene discovery model.
Dis Model Mech
2017
28290208
Reproducibility in biomarker research and clinical development: a global challenge.
Biomark Med
2017
28450744
Bridging the translational innovation gap through good biomarker practice.
Nat Rev Drug Discov
2017
28290208
Reproducibility in biomarker research and clinical development: a global challenge.
Biomark Med
2017
1 - 50 of 112
Column Actions
Search
Recommended Authors
Hailiang Mei
Leiden University Medical Center
Career Start Year
2014
Number of shared co-authors
4
Felix Eichinger
University of Michigan ann arbor
Career Start Year
2006
Number of shared co-authors
2
Suzanne S Fei
Oregon National Primate Research Center
Career Start Year
2005
Number of shared co-authors
3
Arnaud Droit
Centre de Recherche du CHU de Quebec-Universite, Universite Laval
Career Start Year
2005
Number of shared co-authors
0
Wayne Yu
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Career Start Year
2005
Number of shared co-authors
1
Nathalie Pochet
Broad Institute of MIT and Harvard
Career Start Year
2004
Number of shared co-authors
1
Brigham H Mecham
Center for Cancer Innovation, University of Washington
Career Start Year
2003
Number of shared co-authors
0
Purvesh Khatri
University of California San Francisco
Career Start Year
2002
Number of shared co-authors
7
Winston Patrick Kuo
Harvard School of Dental Medicine
Career Start Year
2001
Number of shared co-authors
11
Mikhail G Dozmorov
Virginia Commonwealth University
Career Start Year
2001
Number of shared co-authors
5
Jean Yee Hwa Yang
The University of Sydney
Career Start Year
2001
Number of shared co-authors
2
David K Crossman
University of Alabama at Birmingham
Career Start Year
2000
Number of shared co-authors
0
Yan W Asmann
Mayo Clinic
Career Start Year
2000
Number of shared co-authors
1
Victor Segura
Center for Applied Medical Research (CIMA)
Career Start Year
2000
Number of shared co-authors
2
Shawn Levy
HudsonAlpha Institute for Biotechnology
Career Start Year
1999
Number of shared co-authors
18
Wenjun Ju
University of Michigan ann arbor
Career Start Year
1998
Number of shared co-authors
2
Rajasree Menon
University of Michigan Medical School ann arbor
Career Start Year
1996
Number of shared co-authors
2
Clemens D Cohen
Medical Clinic and Policlinic IV, University of Munich
Career Start Year
1996
Number of shared co-authors
2
Sudhir Varma
Center for Cancer Research, National Cancer Institute
Career Start Year
1994
Number of shared co-authors
2
Gary Hardiman
Institute for Global Food Security, Queen's University Belfast
Career Start Year
1994
Number of shared co-authors
1
Holger S??ltmann
German Cancer Research Center (DKFZ)
Career Start Year
1993
Number of shared co-authors
3
Atul J Butte
Bakar Computational Health Sciences Institute, University of California san francisco
Career Start Year
1993
Number of shared co-authors
2
Matthias Kretzler
University of Michigan ann arbor
Career Start Year
1992
Number of shared co-authors
2
Erwin P Bottinger
Hasso Plattner Institute for Digital Health at Mount Sinai
Career Start Year
1992
Number of shared co-authors
5
Keith A Baggerly
The University of Texas MD Anderson Cancer Center
Career Start Year
1991
Number of shared co-authors
3
Kevin R Coombes
Medical College of Georgia
Career Start Year
1990
Number of shared co-authors
3
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year
1989
Number of shared co-authors
3
John Quackenbush
Harvard T. H. Chan School of Public Health
Career Start Year
1989
Number of shared co-authors
19
Johan Lindberg
Karolinska Institute
Career Start Year
1988
Number of shared co-authors
2
Paul C Boutros
University of California los angeles
Career Start Year
1970
Number of shared co-authors
18
row(s) 1 - 30 of 30
Collaborators
Weida Tong
National Center for Toxicological Research
Co-authored papers
13
Ming Shi
Co-authored papers
10
Huixiao Hong
Co-authored papers
10
Charles Wang
Co-authored papers
7
Dalila B Megherbi
Co-authored papers
7
Rebecca Kusko
Immuneering Corporation
Co-authored papers
7
Baitang Ning
Co-authored papers
7
Joshua Xu
Co-authored papers
7
Frank Staedtler
Co-authored papers
7
Wendell D Jones
Department of Bioinformatics and Clinical Systems
Co-authored papers
6
Christopher E Mason
Feil Family Brain and Mind Research Institute.
Co-authored papers
6
Jonathan Foox
Co-authored papers
6
Wenming Xiao
Human Phenome Institute and Shanghai Cancer Center, Fudan University
Co-authored papers
6
Pierre R Bushel
Co-authored papers
6
Tieliu Shi
Co-authored papers
6
Jessica Nordlund
Uppsala University
Co-authored papers
5
Zhichao Liu
Co-authored papers
5
Cesare Furlanello
Bruno Kessler Foundation
Co-authored papers
5
James C Willey
Co-authored papers
5
Hong Fang
National Center for Toxicological Research (NCTR)
Co-authored papers
5
Wenjun Bao
SAS Institute Inc Cary
Co-authored papers
5
Xiaohui Fan
College of Life Sciences, Zhejiang University
Co-authored papers
4
Quan-Zhen Li
Co-authored papers
4
Wenzhong Xiao
Stanford University
Co-authored papers
4
Ulrika Liljedahl
Co-authored papers
4
Chunlin Xiao
Chongqing Aier Eye Hospital
Co-authored papers
4
Zhiguang Li
Co-authored papers
4
Jean Thierry-Mieg
Co-authored papers
3
Kelci Miclaus
Co-authored papers
3
Roderick V Jensen
Virginia Tech
Co-authored papers
3
1 - 30